| HOME >> MEDICINE >> TECHNOLOGY |
$
253,128$
209,052(a) Includes stock option tax benefit which will reduce taxes in future periods.(b) See footnote (b) to Table 2.Valeant Pharmaceuticals InternationalProforma Organic Growth - by SegmentFor the Three and Twelve Months Ended December 31, 2011(In thousands) Three Month Ending December 31,(a) (b) (a) (c) (d)(e)December 2011December 2010 Total Proforma Acquisitions Total Proforma QTD 2010 Divestitures/ Discontinuations % ChangeDecember 2011 currency impactDecember 2011 excluding currency impact% Change U.S. Dermatology $
51,360$
90,330$
20,083$
8,715$
,69839%$
-$
51,36039% U.S. Neurology & Other (d)195,879201,470-201,470--3%-195,879-3%Total U.S.
347,239291,80020,083310,1851,69812%-347,23912%Canada/Australia100,01779,5738,31287,885-14%271100,28814%Specialty Pharmaceuticals
447,256371,37328,395398,0701,69812%271447,52712%Branded generics -
Latin America65,77169,038-69,038--5%5,49271,2633%Branded generics - Europe141,14448,31091,329139,639-1%8,695149,8397%Branded Generics
206,915117,34891,329208,677--1%14,187221,1026%Total product sales$
54,171$
488,721$
9,724$
,747$
,6988%$
4,458$
8,62910%Add: JV Revenue (f)
1,048177-177--1,048Total$
55,219$
488,898$
9,724$
,924$
,6988%$
4,458$
9,67710% Twelve Months Ended December 31,(a) (b) (a) (c) (d)(e)December 2011December 2010 Total Proforma Acquisitions Total Proforma YTD 2010Divestitures/Discontinuations % ChangeDecember 2011 currency impactDecember 2011 excluding currency impact% Change U.S. Dermatology $
437,663$
306,664$
35,614$
336,923$
5,35532%$
-$
437,66332% U.S. Neurology & Other (d)767,222780,68120,625801,306--4%-767,222-4%Total U.S.
1,204,8851,087,34556,2391,138,2295,3556%-1,204,8856%Canada/Australia334
'/>"/>
| SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2010 PR Newswire. All rights reserved |